158178-93-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Oxazolecarboxamide(9CI) is used as a building block for the synthesis of bioactive molecules, contributing to the development of new drugs and therapeutic agents. Its unique structure allows for the creation of diverse chemical entities with potential medicinal properties.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Oxazolecarboxamide(9CI) serves as a valuable intermediate for the preparation of various organic compounds. Its reactivity and structural features enable the synthesis of a wide range of chemical products, expanding the scope of organic chemistry.
Used in Medicinal Chemistry:
5-Oxazolecarboxamide(9CI) is utilized in medicinal chemistry for the design and synthesis of novel pharmaceutical agents. Its incorporation into drug candidates can potentially enhance their efficacy, selectivity, and pharmacokinetic properties, leading to improved therapeutic outcomes.

InChI:InChI=1/C4H4N2O2/c5-4(7)3-1-6-2-8-3/h1-2H,(H2,5,7)

Upstream product

• 14502-66-0 N-formylpropargylamine 
• 118994-89-1 oxazol-5-yl-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Catalyzed synthesis method of heterocyclic amide compounds

The invention discloses a catalyzed synthesis method of heterocyclic amide compounds. The catalyzed synthesis method includes steps of (1) adding propargyl amide compounds, nitrous acid tert-butyl ester, nitrogen hydroxyl phthalic anhydride, catalyst and

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.